<DOC>
	<DOCNO>NCT02179346</DOCNO>
	<brief_summary>Non-interventional study evaluate safety efficacy NOVOCART® Inject patient full thickness cartilage defect hip .</brief_summary>
	<brief_title>Observational Study With NOVOCART® Inject Reconstruction Hip Joint With Full Thickness Cartilage Defects</brief_title>
	<detailed_description>Prospective multicenter non-interventional study evaluate safety efficacy NOVOCART® Inject patient impingement syndrom hip . Safety : 12-month post treatment follow period measure number adverse drug reactions/serious adverse drug reaction . Efficacy : 12-month post treatment follow period use iHOT 33 EuroQuol-5D-5L .</detailed_description>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>Male female patient 18 60 year Insulated full thickness cartilage damage hip joint ICRS grade 3 Received subchondral bone lamella receive reconstructed labrum labrum cartilage defect defect size ≥ 1.5 ≤ 10 cm2 Intact surround cartilage structure around defect , correspond articular surface existence write informed consent patient Enlightenment More 2 defect 2 correspond defect defect low extremity simultaneously Radiographic sign osteoarthritis Kellgren &amp; Lawrence &gt; 1 Profound bony lesion &gt; 0.5 cm defect area Presence rheumatoid , infectious parainfectious arthritis , well state disease Skin injury limb operate cartilage defect correspond articular surface Existing medication , drug alcohol Acute infectious disease , chronic cardiovascular disease , endocrine metabolic disorder , autoimmune neoplastic disease impairment upper extremity , prevents discharge Crutches Known bleed disorder , Hemophilia A / B thrombophilia pregnancy lactation , represent time treatment contraindication Known allergy ingredient inmates prison</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cartilage defect</keyword>
	<keyword>hip</keyword>
	<keyword>impingement</keyword>
</DOC>